This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/20/2026
Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.
To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.
To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.
Perera et al (2022)1 conducted an open-label, parallel-group study to assess the PK, safety, and tolerability of a single oral 60 mg dose of milvexian in participants with normal renal function and moderate or severe renal impairment.
OBJECTIVE: To assess the effect of moderate and severe renal impairment on the PK properties of milvexian.
STUDY DESIGN: Open-label, nonrandomized, parallel group study of 3 renal function groups.
| Characteristica | Normal renal function (n = 8) | Moderate renal impairment (n = 8) | Severe renal impairment (n = 8) | Total (n = 24) |
|---|---|---|---|---|
| Male gender, n (%) | 7 (87.5) | 6 (75.0) | 5 (62.5) | 18 (75.0) |
| Age, y Median (range) | 53.5 (30 to 67) | 63.0 (46 to 70) | 61.5 (27 to 70) | 60.0 (27 to 70) |
| Race, n (%) White Black or African American Asian Biracial | 6 (75.0) 1 (12.5) 0 1 (12.5) | 7 (87.5) 0 1 (12.5) 0 | 5 (62.5) 3 (37.5) 0 0 | 18 (75.0) 4 (16.7) 1 (4.2) 1 (4.2) |
| BMI, kg/m2 Median (range) | 30.90 (19.6 to 31.5) | 34.60 (24.3 to 37.5) | 32.75 (20.4 to 37.9) | 31.45 (19.6 to 37.9) |
| eGFR, mL/min/1.73 m2 Median (range) | 104.5 (91 to 157) | 49.0 (36 to 59) | 20.5 (9 to 26) | - |
| CrCl, mL/min Median (range) | 125.0 (104 to 174) | 67.0 (44 to 83) | 32.0 (11 to 37) | - |
| aAll values presented as median (minimum-maximum) unless otherwise stated. Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; CrCl, creatinine clearance. Table from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416. | ||||
Mean concentrations of milvexian were higher in participants with moderate or severe renal impairment compared with participants with normal renal function following a single dose of milvexian.1
Mean (±SD) milvexian plasma concentration versus time profile1

Abbreviations: SD, standard deviation.
Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.
PK parameters are summarized in the table below.1
| Parametera | Normal renal function (n = 8) | Moderate renal impairment (n = 8) | Severe renal impairment (n = 8) |
|---|---|---|---|
| Cmax, ng/mL | 462 (30) | 406 (46) | 462 (42) |
| %fu | 8.85 (8) | 8.81 (11) | 8.40 (15) |
| Cmax fu, ng/mL | 40.9 (29) | 35.8 (44) | 38.8 (44) |
| AUC(0-t), ng·h/mL | 3860 (36) | 5004 (34) | 7094 (33) |
| AUC(0-t) fu, ng·h/mL | 341 (33) | 441 (32) | 596 (41) |
| AUC(INF), ng·h/mL | 3916 (36) | 5154 (32) | 7411 (37) |
| AUC(INF) fu, ng·h/mL | 347 (34) | 454 (30) | 623 (44) |
| AUC(0-96), ng·h/mL | 3883 (36) | 5015 (34) | 7167 (35) |
| Tmax, h | 4.50 (4.00–5.00) | 4.75 (4.00–7.00) | 5.00 (4.50–8.00) |
| T½, h | 13.8 (3.45) | 18.0 (5.37) | 17.7 (4.75) |
| CLT/F, L/h | 15.3 (36) | 11.6 (32) | 8.10 (37) |
| CLT/F fu, L/h | 173 (33) | 132 (30) | 96.4 (44) |
| CLR, mL/h | 1617 (52) | 914 (40) | 263 (65) |
| %Urt | 10.5 (45) | 7.64 (33) | 3.14 (75) |
| %Protein binding | 91.1 (1) | 91.1 (1) | 91.5 (1) |
| aCmax, %fu, Cmax fu, AUC(0-t), AUC(0-t) fu, AUC(INF), AUC(INF) fu, AUC(0-96), CLT/F, CLT/F fu, CLR, %Urt, and %protein binding are presented as adjusted geometric mean (%CV); Tmax is presented as median (minimum–maximum); and T½ is presented as mean (SD). Abbreviations: Cmax, maximum observed plasma concentration; fu, fraction of unbound drug; Cmax fu, maximum observed plasma concentration of free drug; AUC(0-t), area under the plasma concentration time curve from time zero to time of the last quantifiable concentration; AUC(0-t) fu, AUC from time zero to time of the last quantifiable concentration of free drug; AUC(INF), AUC from time zero extrapolated to infinite time; AUC(INF) fu, AUC from time zero extrapolated to infinite time of free drug; AUC(0-96), AUC from time zero to 96 h; Tmax, time of maximum observed plasma concentration; T½, terminal plasma half-life; CLT/F, apparent total body clearance; CLT/F fu, apparent total body clearance of free drug; CLR, renal clearance; %Urt, percentage dose of milvexian total amount recovered in urine; %CV, percentage coefficient of variation; SD, standard deviation. Table from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416. | |||
A regression analysis indicated that Cmax was similar for all renal functional groups.1
The AUC(0-T) increased by 39% and 50% in participants with eGFR 30 and 15 mL/min/1.73 m2, respectively, compared to those with normal renal function (eGFR 90 mL/min/1.73 m2). The AUC(0-T) increased by 38% and 49% in participants with CrCl 30 and 15 mL/min, respectively, compared to those with normal renal function (CrCl 90 mL/min).1
The AUC(INF) increased by 41% and 54% in participants with eGFR 30 and 15 mL/min/1.73 m2, respectively, compared to those with normal renal function (eGFR 90 mL/min/1.73 m2). The AUC(INF) increased by 40% and 52% in participants with CrCl 30 and 15 mL/min, respectively, compared to those with normal renal function (CrCl 90 mL/min).1
Predicted Values of Milvexian PK Parameters Based on Renal Impairment From the Regression Analysis of eGFR and CrCl in a) Moderate and b) Severe Renal Impairment1

Abbreviations: PK, pharmacokinetic; eGFR, estimated glomerular filtration rate; CrCl, creatinine clearance; GMR, geometric
mean ratio; CI, confidence interval; Cmax, maximum observed concentration; AUC(0-t), area under the plasma concentration-time curve from
time zero to time of the last quantifiable concentration; AUC(INF), area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.
Mean baseline (predose Day 1) aPTT values were similar across renal function groups and ranged from 23.9 to 25.3 seconds.1
Administration of a single oral dose of milvexian resulted in a concentration-dependent prolongation of aPTT that was similar across all renal function groups.1
Mean (± SD) aPTT Versus Time Profile1
Abbreviations: aPTT, activated partial thromboplastin time; h, hours; SD, standard deviation, sec, seconds.
Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.
There were no deaths or serious AEs leading to discontinuation during the study and no bleeding events were reported.1
A literature search of MEDLINE®
| 1 | Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment. Clin Pharmacokinet. 2022;61(10):1405-1416. |
| 2 | |
| 3 | |
| 4 | |
| 5 |
Would you like to clear and leave your conversation? Message history will be lost.